LGALS3 and neoplasm: In addition, GB1211 reverses the galectin-3-induced inhibition of immune checkpoint inhibitors (pembrolizumab and atezolizumab) binding to programmed cell death protein 1 and PD-L1, thereby reducing tumor resistance to these agents and restoring response to immune checkpoint therapy [28].